Nanjing Hicin Pharmaceutical (300584.SZ) plans to acquire the minority shareholder equity of Anqing Huichen.

Nanjing Hicin Pharmaceutical (300584.SZ) announced that Gu Yuqin, Qian Demin, Lu Shiping, and Jiang Jinyuan, minority shareholders of its controlled subsidiary Anqing Huichen Technology Co., Ltd. (hereinafter referred to as "Anqing Huichen" or "Huichen Technology"), intend to transfer their combined 25% equity interest in Anqing Huichen. The company plans to acquire a total of 10.00% equity interest in Anqing Huichen held by Gu Yuqin, Qian Demin, and Lu Shiping for RMB 64.5083 million, and to acquire 15.00% equity interest in Anqing Huichen held by Jiang Jinyuan for RMB 0. Upon completion of this acquisition, the company's shareholding in Anqing Huichen will increase from 75% to 100%, and Anqing Huichen will become a wholly-owned subsidiary of the company. As Anqing Huichen's electrolyte additives have achieved stable production and supply, the new energy materials business segment has become a new engine for the company's business development and performance growth. This acquisition of minority shareholder equity in Anqing Huichen will help enhance the management decision-making efficiency and core competitiveness of the company's business in this segment, and fully unlock the synergistic value among the listed company and its subsidiaries. Meanwhile, as Anqing Huichen's revenue and profit scale gradually increase, raising the shareholding ratio in Anqing Huichen will help enhance the company's performance and is in line with the interests of the company and its shareholders.